CN105594661A - Establishment method of bone marrow suppression mouse model - Google Patents
Establishment method of bone marrow suppression mouse model Download PDFInfo
- Publication number
- CN105594661A CN105594661A CN201610038158.7A CN201610038158A CN105594661A CN 105594661 A CN105594661 A CN 105594661A CN 201610038158 A CN201610038158 A CN 201610038158A CN 105594661 A CN105594661 A CN 105594661A
- Authority
- CN
- China
- Prior art keywords
- bone marrow
- group
- marrow suppression
- model
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/02—Breeding vertebrates
Abstract
The invention belongs to the technical field of medical science, and particularly relates to an establishment method of a bone marrow suppression mouse model. The problems that at present, a bone marrow suppression animal model is low in modeling rate and poor in repeatability are solved. The method comprises the steps that an NOD or SCID mouse is adopted, the abdominal cavity of the mouse is injected with 150 mg/kg, calculated according to the initial body weight, of cyclophosphamide, injection is conducted every other day, injection is conducted three times in total, the observation period is 15 days, and the bone marrow suppression mouse model can be obtained. According to the method for establishing the bone marrow suppression mouse model, operation is easy, the modeling rate is high, the repeatability is good, the method can be used for various experimental animals, a foundation is laid for research on bone marrow suppression experiments, the bone marrow suppression experiments and clinical application research can be more normalized and standardized, objective and accurate verification on drug efficacy and action mechanisms of various drugs for preventing and treating bone marrow suppression is facilitated, further guidance on selection and evaluation of clinical treatment schemes is facilitated, and guidance on pharmacology experiments and development of new drugs for treating bone marrow suppression is facilitated.
Description
Technical field
The invention belongs to medicine technology field. Be specifically related to a kind of method for building up of bone marrow suppression mouse model.
Background technology
Bone marrow suppression is most of chemotherapy, the total bad reaction of radiotherapy medicine, shows as peripheral blood monosystem or complete set haemocyte subtractsWait less the change of hemopoietic system. Endoxan causes the existing many reports of myelosuppressive research, but adopts endoxan to copyBone marrow suppression model there is no unified standard, and the using dosage of endoxan and time remain in dispute, cause bone marrow suppression animal mouldThe one-tenth mould rate of type is low, repeatable poor, thereby affects its pathogenesis and the myelosuppressive effectiveness study of medical treatment.
How to set up a kind of clear and definite, repeatable bone marrow suppression animal model, to furtheing investigate its pathogenesis and inquiring into itEffectively preventing and treating method, and verify curative effect and the mechanism of action of various anti-bone marrow suppression medicines, is all a vital problem.
Summary of the invention
Object of the present invention is exactly low, the repeatable poor problem of one-tenth mould rate in order to solve current bone marrow suppression animal model, providesA kind of become the method for building up of bone marrow suppression mouse model of high, the favorable repeatability of mould rate. The bone marrow suppression mould of setting up disclosed by the inventionThe method of type, simple to operate, become mould rate high, favorable repeatability, can be for various animals used as test, for bone marrow suppression experiment is groundStudy carefully and lay a good foundation, be conducive to objective, verify and be conducive to the myelosuppressive curative effect of various medical treatments and the mechanism of action accuratelyFurther selection and the evaluation of guiding clinical treatment scheme, the pharmacological evaluation and the exploitation that are conducive to guiding treatment bone marrow suppression new drug are groundSystem.
For achieving the above object, the present invention has adopted following technical scheme:
The method for building up of bone marrow suppression mouse model, selects 55 of NOD/SCID male mices in 6 week age, be divided at random normal group,1 group, control group and model, 2 groups, model, 3 groups, model, 4 groups, model. Except normal group, all the other each group is further divided into a group and (connectsContinuous administration group), b group (next day administration group), totally 11 groups, 5 every group. Model group respectively through abdominal cavity continuously injection and the next dayInjection various dose endoxan (50mg/kg, 100mg/kg, 150mg/kg, 200mg/kg), control group is with physiological saline generationReplace, normal group does not add any intervening measure, observes 15d, evaluates each group of mouse survival rate, PBC number, marrow pathologyForm, marrow hemopoietic stem cells positive rate.
Below by detailed experimental result, the present invention is described---the method for building up of bone marrow suppression mouse model.
1 materials and methods
1.1 material
1.1.1 55 of NOD/SCID male mices in 6 week age are selected in animal used as test and grouping, body weight (23 ± 4) g, and SPF level,Provided by Shanghai Slac Experimental Animal Co., Ltd., raise indoor in Shanghai Univ. of Traditional Chinese Medicine's Experimental Animal Center, room temperature (27± 1) DEG C, edible full nutrition pellet. Adaptability is fed 3 days, is divided at random 5 large group (normal group, control group, moulds1 group, type, 2 groups, model, 3 groups, model, 4 groups, model), except normal group, every group is further divided into a group (successive administration group), bGroup (next day administration group), totally 11 groups, 5 every group.
1.1.2 medicine and reagent cyclophosphamide Injection, purchased from Hengrui Medicine Co., Ltd., Jiangsu Prov.. LineageCellDepletionKit kit, purchased from beautiful day Ni Miltenyi company of Germany. Biotinylated antibody (CD3e, B220, Gr1,Ter119, Mac1), purchased from BDPharmingen company. The micro-magnetic bead of antibiotin (MagneticBeads) is beautiful purchased from GermanyIt Ni Miltenyi company. Sca-1, c-Kit antibody, purchased from eBioscience company.
1.1.3 instrument and equipment LEICA-RM2135 type slicer, LEICA-DME light microscope, the Shanghai micro-system of come cardSystem Co., Ltd. RT-7300 Automatic Blood Cell Analyzer, China Shenzhen Lei Du company. BDAccuriC6 flow cytometer,U.S. company BD.
1.2 method
1.2.1 medication is according to initial body weight administration, and except normal group, control group, all the other each group with endoxan lumbar injection.
Normal group: do not add any intervening measure.
Contrast a group: physiological saline lumbar injection, every day 1 time, continuously 3d.
Contrast b group: physiological saline lumbar injection, the next day 1 time, continuous 3 times.
Model 1a group: 50mg/kg body weight, every day 1 time, continuously 3d.
Model 2a group: 100mg/kg body weight, every day 1 time, continuously 3d.
Model 3a group: 150mg/kg body weight, every day 1 time, continuously 3d.
Model 4a group: 200mg/kg body weight, every day 1 time, continuously 3d.
Model 1b group: 50mg/kg body weight, the next day 1 time, continuous 3 times.
Model 2b group: 100mg/kg body weight, the next day 1 time, continuous 3 times.
Model 3b group: 150mg/kg body weight, the next day 1 time, continuous 3 times.
Model 4b group: 200mg/kg body weight, the next day 1 time, continuous 3 times.
Experiment self administration of medication has started, Continuous Observation 15 days.
1.2.2 the sign that observes the symptoms is tested from starting, weigh weekly 1 time, observe mouse the bodily form, hair color, gait, look for foodAnd active situation, and record animal dead number of elements every day.
1.2.3 PBC number is tested from starting, and within every 3 days, afterbody is got blood 1 time, 50 times of 2mMEDTA/PBS dilutions,Automatic Blood Cell Analyzer detects PBL, red blood cell, platelet count.
1.2.4 observe marrow pathomorphism and put to death mouse with cervical vertebra dislocation method on 15th, get right side femur, 4% paraformaldehyde is fixed24 hours, 10%EDTA decalcifying Fluid decalcification 28d, FFPE, makes respectively 4 continuous paraffin sections of thick about 4m, by stoneWax section is placed in 37 DEG C of baking boxs spend the night after, gradient ethanol rehydration after dimethylbenzene dewaxing, brazilwood extract dyeing 5min, through 1% hydrochloric acidEthanol color separation, running water fully rinses after oil blackeite, then with redying 5min in 0.1% Yihong, finally by gradient ethanol dehydration, dimethylbenzeneAfter transparent, mounting. The change of normal optical Microscopic observation organic slice pathomorphism.
1.2.5 marrow hemopoietic stem cells positive rate is got left side femur, bilateral hipbone, bilateral tibial, is placed in 5ml containing 2mMEDTA'sIn PBS liquid, repeatedly rinse ossis with 3ml syringe, collect whole bone marrow cells, the sorting of Ficoll density－gradient centrifuga－tion methodBMNC cell, MACS rinses 1 time, and LineageCellDepletion immunological magnetic bead sorting Lin-cell is (according to kitOperation), add SAV-FITC, Sca1-PE, c-Kit-APC fluorescence antibody, hatch 30min on ice, MACS rinses 1Time, flow cytometer detects marrow hemopoietic stem cells (Lineage－－Sca1+－c-Kit+, LSK cell) and positive rate.
2 results
2.1 Symptoms
Except normal group, other is respectively organized mouse and after modeling, all occurs gradually body weight, temperature decline, and movable minimizing is slow in reacting,Chilly is curled up sleeping, and chaeta is loose, tarnishes, and food-intake, amount of drinking water reduce, the performances such as hydrouria, 9-after modelingAbout 12 days, above-mentioned symptom reaches top. After modeling the 15th day starts, and above-mentioned symptom alleviates gradually.
2.2 survival rate statistics
Compared with normal group, contrast a group, contrast b group, model 1a group, model 1b group, model 2a group, model 2b groupAnd the appearance death of model 3b group, there is a small amount of death in model 3a group, model 4a group, model 4b group occur at viewing durationMortality or all dead (Fig. 1).
2.3 PBC numbers
We are by the group without dead mouse---normal group, physiological saline a group, physiological saline b group, model 1a group, model1b group, model 2a group, model 2b group and model 3b group PBC number compare, and result is as follows:
2.3.1 leukocyte count
With normal group comparison, physiological saline 1a group, physiological saline 1b group, model 1a group, that model 1b organizes each time point is thin in vainBorn of the same parents' number has no notable difference (P > 0.05). Model 2a group, model 2b group leukocyte count presented downward trend gradually from the 3rd day,Within 9th, start to rise gradually, during to 15 days, substantially recover normal. Model 3b group dropped to minimum point (P < 0.01) in the time of the 6th day,During to 15 days, still remain on reduced levels, with normal group comparison, difference is very significant (P < 0.01) (Fig. 2).
2.3.2 red blood cell number
With normal group comparison, it is red thin that physiological saline 1a group, physiological saline 1b group, model 1a group, model 1b organize each time pointBorn of the same parents' number has no notable difference. Model 2a group, model 2b group, model 3b group red blood cell number presented decline gradually and become from the 3rd dayGesture. Wherein, model 2a group dropped to minimum point in the time of the 9th day, model 2b group dropped to minimum point in the time of the 6th day, thereafterRecover gradually. Model 3b group dropped to minimum point (P < 0.01) in the time of the 12nd day, still remained on reduced levels during to 15 days(P < 0.01) (Fig. 3).
2.3.3 platelet count
With normal group comparison, physiological saline 1a group, physiological saline 1b group, model 1a group, that model 1b organizes each time point blood is littlePlate counting has no notable difference. Model 2a group, model 2b group, model 3b group platelet count presented decline gradually from the 3rd dayTrend, wherein, model 2b group dropped to minimum point in the time of the 9th day, and model 2a group, model 3b group declined in the time of the 12nd dayTo minimum point (P < 0.01) (Fig. 4).
2.4 normal optical sem observation results
Normal optical sem observation normal group, physiological saline 1b group, model 3b group Bone marrow histology pathology form, result is as follows:
Normal group, physiological saline 1b group: bone marrow of mice structural integrity, visible a large amount of red blood cells, monocyte and macronucleus are thinBorn of the same parents, blood sinus is enriched (Fig. 5, Fig. 6).
Model 3b group: bone marrow of mice heavy damage, visible large stretch of cavity, red blood cell, monocyte and megacaryocyte are a large amount ofReduce, blood sinus significantly reduces (Fig. 7).
2.5 marrow hemopoietic stem cells positive rates
Flow cytometer detects physiological saline 1b group, model 3b group marrow LSK cell positive rate, result: with physiological saline 1bGroup contrast, model 3b group LSK cell positive rate obviously reduces, and difference is very significant (P < 0.01) (Fig. 8).
The present invention adopts NOD/SCID mouse, gives the endoxan of lumbar injection various dose, and the observation period is 15d, from depositingThe angle of motility rate, PBC counting, Bone marrow histology pathology form and marrow hemopoietic stem cells positive rate, assesses its marrow and presses downProcessing procedure degree, causes optimal dose and the administration time of bone marrow suppression mouse model to clear and definite endoxan.
Survival rate is evaluated: within the observation period, 200mg/kg successive administration group and the next day administration group, all occur a large amount of dead mouses orAll dead,, also there is part dead mouse (Fig. 1) in 150mg/kg successive administration group, and obviously these groups all do not meet foundationThe condition of animal model. Therefore got rid of application 200mg/kg successive administration group or the next day administration and 150mg/kg successive administrationSet up the possibility of bone marrow suppression model. This is also that this reason of several groups is not included in our follow-up study in.
PBC number is evaluated: 50mg/kg successive administration group and the next day administration group, at leucocyte, red blood cell, blood platelet meterNumber aspect, with normal group and the comparison of physiological saline control group, all no significant differences. Therefore, these two groups do not meet yet and set up animalThe condition of model. 100mg/kg successive administration group and the next day administration group all occur that blood three is the decline of cell, but white blood cell count(WBC)Start to return to gradually normally at 12d, therefore these two groups neither best modeling group. Administration group next day of 150mg/kg, blood threeBe cell (leucocyte, red blood cell, blood platelet), within the whole observation period, all occur obviously reducing, with normal group, physiological salineAdministration group comparison next day of successive administration group and physiological saline, difference is very significant (P < 0.01) (Fig. 2-Fig. 4).Therefore, we enter follow-up study using this group as optimal candidate group, after also getting rid of thus continuous normal saline administration group being enteredThe continuous possibility of evaluating.
Bone marrow histology pathology form is evaluated: administration group next day of 150mg/kg, and bone marrow of mice heavy damage, visible large stretch of cavity,Red blood cell, monocyte and megacaryocyte reduce in a large number, and blood sinus significantly reduces, and meet the expection (figure that sets up bone marrow suppression model7). Administration group and normal group comparison next day of physiological saline, bone marrow of mice structural integrity, all visible a large amount of red blood cell, monokaryonCell and megacaryocyte, blood sinus is abundant. These two groups of Bone marrow histology pathology forms have no notable difference (Fig. 5-Fig. 6). So far,Administration group comparison next day of normal group and physiological saline, two groups mouse survival rate, PBC counting, Bone marrow histology pathology shapeThe equal no significant difference in state aspect. Therefore, consider from the angle of research baseline consistent (intervening measure is identical), normal group is included inFollow-up study is meaningless.
Marrow hemopoietic stem cells positive rate: administration group contrast administration group and physiological saline next day next day of 150mg/kg, LSK cellPositive rate obviously reduces, and difference is very significant (P < 0.01) (Fig. 8). The next day that this also confirming 150mg/kg again toMedicine group is to meet the scheme of setting up bone marrow suppression model.
In sum, administration group next day of 150mg/kg, mouse is without death, and peripheral blood three is that cell obviously reduces, myeloid tissuePathomorphism obviously destroys, marrow hemopoietic stem cells significantly reduces, and reaches the object of setting up bone marrow suppression model. Illustrate and adopt abdomenChamber injection endoxan method, the next day that intervening measure being 150mg/kg, once, continuous 3 times, the observation period is 15d, it is suitable to obtainBone marrow suppression mouse model.
The method of setting up bone marrow suppression model disclosed by the invention, simple to operate, become mould rate high, favorable repeatability, can be forVarious animals used as test, lay a good foundation for bone marrow suppression experimental study, make myelosuppressive experiment and clinical application research moreStandardization, standardization, be conducive to objective, verify the myelosuppressive curative effect of various medical treatments and the mechanism of action accurately, favourableIn selection and the evaluation of further guiding clinical treatment scheme, be conducive to pharmacological evaluation and the exploitation of guiding treatment bone marrow suppression new drugDevelopment.
Brief description of the drawings
Accompanying drawing 1 is each group of mouse viewing duration survival condition statistics.
Accompanying drawing 2 is each group of mouse viewing duration leukocyte count statistics.
Accompanying drawing 3 is each group of mouse viewing duration red blood cell number statistics.
Accompanying drawing 4 is each group of mouse viewing duration platelet count statistics.
Accompanying drawing 5 is normal group bone marrow of mice pathomorphism picture.
Accompanying drawing 6 is physiological saline 1b group bone marrow of mice pathomorphism picture.
Accompanying drawing 7 is model 3b group bone marrow of mice pathomorphism picture.
Accompanying drawing 8 is physiological saline 1b group, the contrast of model 3b group mouse bone marrow cells LSK cell positive rate.
Accompanying drawing 9 is control group on the 15th, the comparison of model group mouse peripheral blood leukocyte count after modeling.
Accompanying drawing 10 is that after modeling, control group, model group mouse red blood cell on the 15th are counted comparison.
Accompanying drawing 11 is that after modeling, control group, model group mouse platelets on the 15th are counted comparison.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the invention will be further described. Following embodiment can make those skilled in the art moreUnderstand all sidedly the present invention.
The method for building up of embodiment bone marrow suppression mouse model
10 of NOD/SCID male mices in 6 week age are selected in 1 animal used as test and grouping, body weight (23 ± 4) g, and SPF level, byShanghai Slac Experimental Animal Co., Ltd. provides, raise indoor in Shanghai Univ. of Traditional Chinese Medicine's Experimental Animal Center, room temperature (27 ±1) DEG C, edible full nutrition pellet. Adaptability is fed 3 days, is divided at random 2 groups (control group, model group), every group5.
2 medications are according to initial body weight administration, and experiment self administration of medication has started, Continuous Observation 15 days.
Control group: physiological saline lumbar injection, the next day 1 time, continuous 3 times.
Model group: 150mg/kg body weight, the next day 1 time, continuous 3 times.
3 sample collections the 15th day, afterbody is got blood 1 time, 50 times of 2mMEDTA/PBS dilutions, Automatic Blood Cell AnalyzerDetect PBL, red blood cell, platelet count. Get right side femur, normal optical Microscopic observation organic slice pathology shapeState. Get left side femur, bilateral hipbone, bilateral tibial, be placed in the PBS liquid of 5ml containing 2mMEDTA, inject with 3mlDevice rinses ossis repeatedly, collects whole bone marrow cells, and flow cytometer detects marrow hemopoietic stem cells (Lineage－－Sca1+－c-Kit+, LSK cell) and positive rate.
4 results
4.1 PBCs are counted comparison
With control group comparison, model group PBL, red blood cell, platelet count all obviously decline, and difference has conspicuousness meaningJustice (P < 0.01) (Fig. 9-Figure 11).
4.2 marrow Pathomorphologic observations
Control group: bone marrow of mice structural integrity, visible a large amount of red blood cells, monocyte and megacaryocyte, the abundant (figure of blood sinus6)。
Model group: bone marrow of mice heavy damage, visible large stretch of cavity, red blood cell, monocyte and megacaryocyte subtract in a large numberFew, blood sinus significantly reduces (Fig. 7).
4.3 marrow hemopoietic stem cells positive rate comparisons
With the contrast of control group group, model group LSK cell positive rate obviously reduces, and difference is very significant (P < 0.01)(Fig. 8).
In sum, the method for setting up bone marrow suppression model disclosed by the invention, simple to operate, become mould rate high, favorable repeatability,Can, for various animals used as test, lay a good foundation for bone marrow suppression experimental study, be conducive to objective, verify various medicines accuratelyThing is prevented and treated myelosuppressive curative effect and the mechanism of action, is conducive to selection and the evaluation of further guiding clinical treatment scheme, is conducive toThe pharmacological evaluation of guiding treatment bone marrow suppression new drug with develop. The present invention meets patent of invention requirements and condition, therefore comply withMethod proposes application for a patent for invention.
Claims (3)
1. a method for building up for bone marrow suppression mouse model, is characterized in that the method adopts NOD/SCID mouse, abdominal cavity notePenetrate endoxan 150mg/kg (calculating by initial body weight), the next day 1 time, inject 3 times, 15 days observation periods, can obtain marrowSuppress mouse model.
2. the method for building up of bone marrow suppression mouse model according to claim 1, is characterized in that wherein said experiment miceIt is NOD/SCID mouse.
3. the method for building up of bone marrow suppression mouse model according to claim 1, is characterized in that wherein said experiment miceIt is the mouse of various experiments germline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610038158.7A CN105594661A (en) | 2016-01-20 | 2016-01-20 | Establishment method of bone marrow suppression mouse model |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610038158.7A CN105594661A (en) | 2016-01-20 | 2016-01-20 | Establishment method of bone marrow suppression mouse model |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105594661A true CN105594661A (en) | 2016-05-25 |
Family
ID=55975482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610038158.7A Pending CN105594661A (en) | 2016-01-20 | 2016-01-20 | Establishment method of bone marrow suppression mouse model |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105594661A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109425523A (en) * | 2017-09-05 | 2019-03-05 | 上海新培晶医学检验所有限公司 | Marrow specimen processing method, decalcifying Fluid and purposes |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007060918A (en) * | 2005-08-29 | 2007-03-15 | Fumakilla Ltd | Composition comprising mite antigen |
| JP2010268686A (en) * | 2009-05-19 | 2010-12-02 | Kanazawa Univ | Excessive esrage expression mouse |
| CN102792919A (en) * | 2012-08-08 | 2012-11-28 | 上海交通大学 | Method of establishing gnotobiotic animal obesity model and application of model |
| CN103911342A (en) * | 2013-01-08 | 2014-07-09 | 中国人民解放军第二军医大学 | Mice animal model of giant cell tumor of bone of human and construction method thereof |
| CN104335970A (en) * | 2013-08-05 | 2015-02-11 | 应哲康 | Method for building human psoriasis mouse model and application of model |
| CN105052830A (en) * | 2015-08-04 | 2015-11-18 | 施军平 | Fatty-liver-related liver cancer model building method based on knockout mice |
-
2016
- 2016-01-20 CN CN201610038158.7A patent/CN105594661A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007060918A (en) * | 2005-08-29 | 2007-03-15 | Fumakilla Ltd | Composition comprising mite antigen |
| JP2010268686A (en) * | 2009-05-19 | 2010-12-02 | Kanazawa Univ | Excessive esrage expression mouse |
| CN102792919A (en) * | 2012-08-08 | 2012-11-28 | 上海交通大学 | Method of establishing gnotobiotic animal obesity model and application of model |
| CN103911342A (en) * | 2013-01-08 | 2014-07-09 | 中国人民解放军第二军医大学 | Mice animal model of giant cell tumor of bone of human and construction method thereof |
| CN104335970A (en) * | 2013-08-05 | 2015-02-11 | 应哲康 | Method for building human psoriasis mouse model and application of model |
| CN105052830A (en) * | 2015-08-04 | 2015-11-18 | 施军平 | Fatty-liver-related liver cancer model building method based on knockout mice |
Non-Patent Citations (2)
| Title |
|---|
| 付林林等: "SCID小鼠－人白血病模型中关键因素的分析", 《中国实验血液学杂志》 * |
| 聂小蒙等: "SCID小鼠-人白血病模型在白血病研究中的应用", 《中国实验血液学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109425523A (en) * | 2017-09-05 | 2019-03-05 | 上海新培晶医学检验所有限公司 | Marrow specimen processing method, decalcifying Fluid and purposes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432324A (en) | Traditional Chinese medicine preparation for treating dysmenorrhoea and preparation method thereof | |
| CN104546992A (en) | Folium cortex eucommiae extract as well as preparation method and application thereof | |
| CN103735825A (en) | Comprehensive conditioning traditional Chinese medicine composition and application thereof | |
| CN107184897A (en) | Composition with invigorating Qi and tonifying kidney effect and preparation method thereof | |
| CN102335394B (en) | Chinese medicinal composition for treating cervical erosion and preparation method thereof | |
| CN102319400B (en) | Traditional Chinese drug composition for blood cooling, hemostasis, yin nourishing, blood stasis dissipating, liver nourishing and eyesight improving, and preparation method thereof | |
| CN105594661A (en) | Establishment method of bone marrow suppression mouse model | |
| CN102935144B (en) | Drug for treating climacteric syndrome and preparation process of drug | |
| CN105395771B (en) | A kind of new warm kidney production of sperm drink and preparation method thereof | |
| CN103655910B (en) | Application of compound thrombosis capsule inn aspect of liver protection | |
| CN102846793A (en) | Composition for stagnant blood constitution, and preparation method and application of composition | |
| CN103285173B (en) | A kind of Chinese medicine treating thrombocytopenic purpura | |
| CN104147180A (en) | Medicine composition for treating immune thrombocytopenic purpura and preparation method thereof | |
| CN101700394B (en) | Pharmaceutical composite for curing colon cancer and preparing method thereof | |
| CN100566743C (en) | A kind of Chinese herbal medicine that suppresses tumor and preparation method thereof | |
| Nie et al. | Establishment of a mouse thrombocytopenia model induced by cyclophosphamide | |
| CN104784354B (en) | A kind of Chinese medicine acupoint injection therapy liquid and its preparation method treating migraine | |
| CN106035210B (en) | Method for establishing acute plateau hypoxia and anxiety stress response animal model | |
| CN104147419A (en) | Traditional Chinese medicine composition for treating immune thrombocytopenia | |
| CN106309413B (en) | The purposes of sesquiterpene derivative and its pharmaceutical composition in agalloch eaglewood | |
| CN103877509B (en) | A kind of medicine and its preparation method treating leukemia | |
| CN1453029A (en) | Chinese medicine composition for treating senile dementia | |
| CN103142862B (en) | Oral liquid capable of regulating immune function and delaying senescence, and preparation method thereof | |
| CN103169834A (en) | Traditional Chinese medicine composition for treating refractory thrombocytopenia | |
| CN102872253A (en) | Composition for deficiency of blood, preparation method and application of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160525 |